Abstract: The present invention relates to derivatives of benzimidazoles of formula (I) as disclosed herein as well as pharmaceutical compositions comprising said derivatives. The derivates according to the present invention are serine/threonine and tyrosine kinase-inhibitors, particularly of PIM1-3- and DYRK1A-kinases and may particularly be used in the treatment of diseases linked to these kinases, such as e.g. leukemias, lymphomas, solid tumors and autoimmune disorders.

Abstract: Disclosed are substituted tricyclic benzimidazoles compounds as defined herein in formula (I) or pharmaceutically acceptable salts thereof. The compounds of the invention selectively inhibit CDK8 and are therefore useful for treating diseases related to this kinase, especially colorectal and melanoma cancers and other solid and hemathological malignancies, autoimmune diseases and inflammatory diseases. Also disclosed are processes for preparing these compounds.

Abstract: The present invention relates to derivatives of benzimidazoles of formula (I) as disclosed herein as well as pharmaceutical compositions comprising said derivatives. The derivates according to the present invention are serine/threonine and tyrosine kinase-inhibitors, particularly of PIM1-3- and DYRK1A-kinases and may particularly be used in the treatment of diseases linked to these kinases, such as e.g. leukemias, lymphomas, solid tumors and autoimmune disorders.

Abstract: The present invention relates to derivatives of benzimidazoles of formula (I) as disclosed herein as well as pharmaceutical compositions comprising said derivatives. The derivates according to the present invention are serine/threonine and tyrosine kinase-inhibitors, particularly of PIM1-3- and DYRK1A-kinases and may particularly be used in the treatment of diseases linked to these kinases, such as e.g. leukemias, lymphomas, solid tumors and autoimmune disorders.

Abstract: The present invention relates to derivatives of benzimidazoles of formula (I) as disclosed herein as well as pharmaceutical compositions comprising said derivatives. The derivates according to the present invention are serine/threonine and tyrosine kinase-inhibitors, particularly of PIM1-3- and DYRK1A-kinases and may particularly be used in the treatment of diseases linked to these kinases, such as e.g. leukemias, lymphomas, solid tumors and autoimmune disorders.

Abstract: Disclosed are substituted tricyclic benzimidazoles compounds as defined herein in formula (I) or pharmaceutically acceptable salts thereof. The compounds of the invention selectively inhibit CDK8 and are therefore useful for treating diseases related to this kinase, especially colorectal and melanoma cancers and other solid and hemathological malignancies, autoimmune diseases and inflammatory diseases. Also disclosed are processes for preparing these compounds.

Abstract: Novel 5-substituted-2-arylpyridine compounds are provided. Such compounds can act as selective modulators of CRP receptors. The 5-substituted-2-arylpyridine compounds provided herein are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds provided are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.

Abstract: Novel aryl substituted imidazopyrazines, imidazopyrimidines, and imidazopyridines are provided. Such compounds can act as selective modulators of CRF receptors. The imidazopyrazines, imidazopyrimidines, and imidazopyridines compounds provided herein are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds provided are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.

Abstract: Arylpyrazine compounds are provided, including arylpyrazines that can bind with high affinity and high selectivity to CRF1 receptors, including human CRF1 receptors. The invention thus includes methods for treatment of disorders and diseases associated with CRF1 receptors, including CNS-related disorders and diseases, particularly affective disorders and diseases, and acute and chronic neurological disorders and diseases.

Abstract: A cable hanger having shell halves adapted to mate with each other, the shell halves each having an inner surface adapted to cooperate with the other to secure the cable within a cable space. The mating of the shell halves is releasably secured by a means for closure. A bolt hole through at least one of the shell halves allows easy mounting of the cable hanger. The shell halves each having, along a vertical mating surface, a means for interlocking adapted to interlock with the means for interlocking of a second cable hanger positioned against the cable hanger along the vertical mating surface. A connection side of the cable hanger may be adapted to have a means for latching to couple with a third cable hanger, positioned connection side to connection side with the cable hanger. The cable hanger allowing additional cables to be added without modifying the mounting of the base hanger.

Abstract: Novel 5-substituted-2-arylpyrazine compounds are provided. Such compounds can act as selective modulators of CRF receptors. The 5-substituted-2-arylpyrazine compounds provided herein are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds provided are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.

Abstract: A cable hanger having shell halves adapted to mate with each other, the shell halves each having an inner surface adapted to cooperate with the other to secure the cable within a cable space. The mating of the shell halves is releasably secured by a means for closure. A bolt hole through the shell halves allows easy mounting of the cable hanger. The shell halves each having, along a vertical mating surface, a means for interlocking adapted to interlock with the means for interlocking of a second cable hanger positioned against the cable hanger along the vertical mating surface. A connection side of the cable hanger may be adapted to have a means for latching to couple with a third cable hanger, positioned connection side to connection side with the cable hanger. The cable hanger allowing additional cables to be added without modifying the mounting of the base hanger.

Abstract: Substituted heteroaryl fused pyridine, pyrazine, and pyrimidine compounds that act as selective modulators of CRF 1 receptors are provided. These compounds are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of the invention are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.

Abstract: A cable hanger having shell halves adapted to mate with each other, the shell halves each having an inner surface adapted to cooperate with the other to secure the cable within a cable space. The mating of the shell halves is releasably secured by a means for closure. A bolt hole through the shell halves allows easy mounting of the cable hanger. The shell halves each having, along a vertical mating surface, a means for interlocking adapted to interlock with the means for interlocking of a second cable hanger positioned against the cable hanger along the vertical mating surface. A connection side of the cable hanger may be adapted to have a means for latching to couple with a third cable hanger, positioned connection side to connection side with the cable hanger. The cable hanger allowing additional cables to be added without modifying the mounting of the base hanger.

Abstract: A sealing assembly for a cable to apparatus interconnection formed by a plurality of shells adapted to mate together, surrounding the interconnection within an interconnection space. When mated together, the shells forming openings for the cable and the apparatus at an apparatus end and a cable end, respectively. A gasket mounted to each shell along a mating surface between the shells and along the openings environmentally seals the interconnection space. A locking rib projecting inward from the shell(s) may be applied to rotationally interlock a coupling nut of the interconnection with the sealing assembly. In a two shell embodiment, a locking band positioned around an outer diameter of the mated together shells with an end to end retaining means may be used to secure the shells together. Alternatively, if three shells are used, the shells may be hinged together and a retaining means applied to join the unhinged ends together.

Abstract: A sealing assembly for a cable to apparatus interconnection formed bya plurality of shells adapted to mate together, surrounding the interconnection within an interconnection space. When mated together, the shells forming openings for the cable and the apparatus at an apparatus end and a cable end, respectively. A gasket mounted to each shell along a mating surface between the shells and along the openings environmentally seals the interconnection space. A locking rib projecting inward from the shell(s) may be applied to rotationally interlock a coupling nut of the interconnection with the sealing assembly. In a two shell embodiment, a locking band positioned around an outer diameter of the mated together shells with an end to end retaining means may be used to secure the shells together. Alternatively, if three shells are used, the shells may be hinged together and a retaining means applied to join the unhinged ends together.

Abstract: Arylpyrazine compounds are provided, including arylpyrazines that can bind with high affinity and high selectivity to CRF1 receptors, including human CRF1 receptors. The invention thus includes methods for treatment of disorders and diseases associated with CRF1 receptors, including CNS-related disorders and diseases, particularly affective disorders and diseases, and acute and chronic neurological disorders and diseases.

Abstract: A line hanger for securing lines, such as transmission, pneumatic, hydraulic, electrical and other types of lines, to a support structure. The line hanger includes a wire structure with an attachment section configured for mounting to the support structure and a pair of clamping arms depending outwardly from the attachment provision. The clamping arms are configured to resiliently separate to receive a line and to resiliently relax for applying a clamping force to secure the line. The clamping arms are clasped together by engaging hook members defined at the open end of the wire structure. Multiple line hangers may be interlinked or stacked relative to the support structure for support multiple lines.

Abstract: Substituted heteroaryl fused pyridine, pyrazine, and pyrimidine compounds that act as selective modulators of CRF 1 receptors are provided. These compounds are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of the invention are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.

Abstract: 5-aryl-Pyrazolo[4,3-d]pyrimidines, 6-aryl-Pyrazolo[3,4-d]pyrimidines and related compounds, as well as other chemically related compounds, that act as selective modulators of CRF 1 receptors are provided. These compounds are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of the invention are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.